BAMBUSA AESCULUS
- Manufacturer
- URIEL PHARMACY INC.
- Effective date
- 2020-12-18
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- full-release
- Hydrated at
- 2026-06-01 02:14:02
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
INDICATIONS & USAGE SECTION
Directions: FOR TOPICAL USE ONLY.
DOSAGE & ADMINISTRATION SECTION
Apply to skin as needed. Under age 2: Consult a doctor.
OTC - ACTIVE INGREDIENT SECTION
Active Ingredients: Bambusa (Bamboo) 6X, Betonica (Wood betony) 6X, Rosmarinus (Rosemary) 6X, Formica (Red wood ant) 7X, Disci intervert. (Bovine intervertebral discs of the cervical, thoracic and lumbar spine) 8X, Jasper 12X, Arnica 20X, Aesculus (Horse chestnut seed) 50X
INACTIVE INGREDIENT SECTION
Inactive Ingredients: Distilled water, Glycerin, Boric acid, Sodium alginate, Lavender oil, Rosemary oil,Sodium hydroxide, Sorbic acid, Tea tree oil, Grapefruit seed extract
OTC - PURPOSE SECTION
Use: Temporary relief of headache.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
KEEP OUT OF REACH OF CHILDREN.
WARNINGS SECTION
Warnings: FOR EXTERNAL USE ONLY.
Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated. Do not use if allergic to any ingredient. Consult a doctor before use for serious conditions, if conditions worsen or persist, or accidental ingestion occurs. If pregnant or nursing, consult a doctor before use. Do not use if safety seal is broken or missing. Avoid contact with eyes.
OTC - QUESTIONS SECTION
Questions? Call 866.642.2858
Made with care by Uriel, East Troy, WI 53120
www.urielpharmacy.com
Lot:
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 48951-2003-5 | BAMBUSA AESCULUS | 60 g in 1 TUBE | GEL | 60 | 3 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 48951-2003 | BAMBUSA AESCULUS GEL [URIEL PHARMACY INC.] | 3 | Legacy NDC, 1 package rows | 20201219_623de1d5-592a-420d-a758-67e973694e8d.zip |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARNICA MONTANA | ACTIVE INGREDIENT | O80TY208ZW | 1 | |
| BAMBUSA VULGARIS WHOLE | ACTIVE INGREDIENT | WCD45M1BSK | 1 | |
| BOS TAURUS INTERVERTEBRAL DISC | ACTIVE INGREDIENT | 0A04Z76C13 | 1 | |
| FORMICA RUFA | ACTIVE INGREDIENT | 55H0W83JO5 | 1 | |
| HORSE CHESTNUT | ACTIVE INGREDIENT | 3C18L6RJAZ | 1 | |
| ROSMARINUS OFFICINALIS FLOWERING TOP | ACTIVE INGREDIENT | 8JM482TI79 | 1 | |
| SILICON DIOXIDE | ACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| STACHYS OFFICINALIS | ACTIVE INGREDIENT | UO9989Y17N | 1 | |
| ARNICA MONTANA | ACTIVE MOIETY | O80TY208ZW | 1 | |
| BAMBUSA VULGARIS WHOLE | ACTIVE MOIETY | WCD45M1BSK | 1 | |
| BOS TAURUS INTERVERTEBRAL DISC | ACTIVE MOIETY | 0A04Z76C13 | 1 | |
| FORMICA RUFA | ACTIVE MOIETY | 55H0W83JO5 | 1 | |
| HORSE CHESTNUT | ACTIVE MOIETY | 3C18L6RJAZ | 1 | |
| ROSMARINUS OFFICINALIS FLOWERING TOP | ACTIVE MOIETY | 8JM482TI79 | 1 | |
| SILICON DIOXIDE | ACTIVE MOIETY | ETJ7Z6XBU4 | 1 | |
| STACHYS OFFICINALIS | ACTIVE MOIETY | UO9989Y17N | 1 | |
| CITRUS PARADISI SEED | INACTIVE INGREDIENT | 12F08874Y7 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| LAVENDER OIL | INACTIVE INGREDIENT | ZBP1YXW0H8 | 1 | |
| POTASSIUM SORBATE | INACTIVE INGREDIENT | 1VPU26JZZ4 | 1 | |
| ROSEMARY OIL | INACTIVE INGREDIENT | 8LGU7VM393 | 1 | |
| SODIUM ALGINATE | INACTIVE INGREDIENT | C269C4G2ZQ | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Products#
Every source-derived product name is available through these pages.
- BAMBUSA AESCULUS
- SORBIC ACID
- BORIC ACID
- WATER
- GLYCERIN
- SODIUM ALGINATE
- LAVENDER OIL
- ROSEMARY OIL
- SODIUM HYDROXIDE
- CITRUS PARADISI SEED
- BAMBUSA VULGARIS WHOLE
- STACHYS OFFICINALIS
- ROSMARINUS OFFICINALIS FLOWERING TOP
- FORMICA RUFA
- BOS TAURUS INTERVERTEBRAL DISC
- SILICON DIOXIDE
- ARNICA MONTANA
- HORSE CHESTNUT
- TEA TREE OIL
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 48951-2003 | 48951-2003-5 |
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SHAMPOO / TOPICAL | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / TOPICAL | 1971 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION / ORAL | 1000 mg/15ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SOLUTION/ DROPS / OPHTHALMIC | 0.47 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM, AUGMENTED / TOPICAL | 55 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / NASAL | 25 mg/1ml | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / BUCCAL | 34 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / TOPICAL | 1720 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SYRUP / ORAL | 2 mg/1ml | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | AEROSOL, FOAM / TOPICAL | 8 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION/ DROPS / OPHTHALMIC | 2.5 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, EXTENDED RELEASE / ORAL | 265 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, COATED / ORAL | 14.21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TOPICAL | 500 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / AURICULAR (OTIC) | 25 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET, EXTENDED RELEASE / ORAL | 0.2 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LIQUID / TOPICAL | 0.25 %w/w | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SPRAY, METERED / NASAL | 0.06 mg | ||
| LAVENDER OIL | LAVENDER OIL | ZBP1YXW0H8 | GEL / TOPICAL | 0.1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | OINTMENT / TOPICAL | NA | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | CREAM / TOPICAL | 0.25 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | TABLET, EXTENDED RELEASE / ORAL | 627 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LOZENGE / ORAL | 1274 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE, DENTIFRICE / DENTAL | 18 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / NASAL | 10 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | TABLET / ORAL | 6 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DOUCHE / VAGINAL | 1 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / TOPICAL | 18144 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / ORAL | 42 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAVENOUS | 15 %w/v | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | SUSPENSION / ORAL | 400 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | SUSPENSION / ORAL | 49 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | SYRUP / ORAL | 3 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPRAY, METERED / NASAL | 13 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / OPHTHALMIC | 6 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GEL / TRANSDERMAL | 500 mg | ||
| POTASSIUM SORBATE | POTASSIUM SORBATE | 1VPU26JZZ4 | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / AURICULAR (OTIC) | 63.64 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CAPSULE, LIQUID FILLED / ORAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | GUM, CHEWING / BUCCAL | 230 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| b6bf71c5-f0e9-b311-e053-2a95a90a5546 | 623de1d5-592a-420d-a758-67e973694e8d | 2020-12-18 | Warnings | b6bf71c5-f0e9-b311-e053-2a95a90a5546 623de1d5-592a-420d-a758-67e973694e8d |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
